Details of Disease

General Information of Disease (ID: DISJUQ5T)

Disease Name	Inflammation
Synonyms	inflammatory disease; inflammatory disorder; anatomical structure inflammation; inflammation of anatomical structure
Disease Class	1A00-CA43: Postoperative inflammation
Definition	A disease involving a pathogenic inflammatory response in the anatomical structure.
Disease Hierarchy	DISH7H5I: Human disease DISJUQ5T: Inflammation
ICD Code	ICD-11 ICD-11: 1A00-CA43.1
Disease Identifiers	MONDO ID MONDO_0021166 MESH ID D007249 UMLS CUI C1290884 MedGen ID 452939 SNOMED CT ID 128139000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 33 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aceclofenac	DMZDF0B	Approved	Small molecular drug	[1]
Aescin	DMFESG7	Approved	Small molecular drug	[1]
Alclometasone	DMAE84F	Approved	Small molecular drug	[2]
Amcinonide	DMM1JL9	Approved	Small molecular drug	[3]
Ampiroxicam	DM5BS98	Approved	Small molecular drug	[1]
Amtolmetin guacil	DMAWU35	Approved	Small molecular drug	[1]
Atorvastatin	DMF28YC	Approved	Small molecular drug	[4]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[5]
Betamethasone Benzoate	DMRMS1A	Approved	Small molecular drug	[1]
Betamethasone butyrate propion	DMZIKTU	Approved	Small molecular drug	[1]
Bromfenac	DMKB79O	Approved	Small molecular drug	[6]
Choline salicylate	DM8P137	Approved	Small molecular drug	[1]
Ciprofloxacin XR	DM2NLS9	Approved	Small molecular drug	[7]
Desoximetasone	DM4PXF6	Approved	Small molecular drug	[8]
Exenatide	DMYHBKN	Approved	Small molecular drug	[9]
Fluocinolone Acetonide	DMG2KI4	Approved	Small molecular drug	[10]
Fluocinonide	DM65KL8	Approved	Small molecular drug	[11]
Flurandrenolide	DMHCI9S	Approved	Small molecular drug	[12]
Folic Acid	DMEMBJC	Approved	Small molecular drug	[13]
Guaimesal	DMR43UY	Approved	Small molecular drug	[1]
Halobetasol Propionate	DM3GB6S	Approved	Small molecular drug	[2]
Halometasone	DMKI1F6	Approved	Small molecular drug	[1]
Hydrocortamate	DM8K1XO	Approved	Small molecular drug	[14]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[15]
Imidazole salicylate	DM3VS7Z	Approved	Small molecular drug	[16]
Interferon gamma	DMHW40I	Approved	NA	[17]
Loxoprofen gel	DMQMGXV	Approved	Small molecular drug	[1]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[18]
Paramethasone	DM6PR40	Approved	Small molecular drug	[19]
Prednicarbate	DMBUNVW	Approved	Small molecular drug	[20]
Prednisone	DM2HG4X	Approved	Small molecular drug	[21]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[22]
Urapidil	DMD59GI	Approved	Small molecular drug	[23]
------------------------------------------------------------------------------------


⏷ Show the Full List of 33 Drug(s)

This Disease is Treated as An Indication in 36 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anti-IL-23	DMX0PWV	Phase 3	Antibody	[24]
FPL-62064	DMGF8MZ	Phase 3	Small molecular drug	[25]
Naproxcinod	DMKP45D	Phase 3	Small molecular drug	[26]
VAP-1 monoclonal antibody	DME0ZRK	Phase 2a	NA	[27]
VX-702	DMKJDR6	Phase 2a	Small molecular drug	[28]
Ab-01	DMOGDCQ	Phase 2	Antibody	[29]
CHR-2797	DMULZ4W	Phase 2	Small molecular drug	[30]
Golotimod	DMKZN3A	Phase 2	Small molecular drug	[31]
IW-6118	DMP42W1	Phase 2	NA	[32]
KDT-501	DM8R3GM	Phase 2	Small molecular drug	[33]
NCX-4016	DMOX1CU	Phase 2	Small molecular drug	[34]
NPC-15199	DME6KAF	Phase 2	Small molecular drug	[35]
PUR-0110	DMVUGF7	Phase 2	NA	[36]
Saratin	DMUE0AK	Phase 2	NA	[37]
VR096	DMKY2BR	Phase 2	NA	[38]
ZYI-1	DMR4E1C	Phase 2	NA	[39]
AMG-191	DMSHK23	Phase 1	NA	[40]
AZD6793	DM5GRZV	Phase 1	Small molecule	[41]
CHR-5154	DMK1Y6M	Phase 1	NA	[42]
CNT0-5	DMPDLV2	Phase 1	NA	[43]
CYT-013-IL1bQb	DMNICD4	Phase 1	Vaccine	[44]
GS-1427	DMDDBG1	Phase 1	NA	[45]
IPL 550,260	DMPKH6Y	Phase 1	NA	[46]
ISIS-APOCIII	DMX3FN4	Phase 1	Antisense drug	[47]
ISIS-CRP	DMQDUG4	Phase 1	Antisense drug	[47]
MIST-B03	DMY1ZRX	Phase 1	NA	[48]
P-3914	DMV22D3	Phase 1	NA	[49]
PS-873266	DMIVOV6	Phase 1	NA	[50]
SAR441566	DMG2YW2	Phase 1	Small molecule	[51]
SAR442970	DM3DHWE	Phase 1	Nanobody	[52]
SAR444336	DMJD82E	Phase 1	NA	[52]
SAR444419	DMQICTG	Phase 1	Nanobody	[52]
SAR444559	DM4OMYQ	Phase 1	Antibody	[52]
SD-118	DMIKZ66	Phase 1	NA	[53]
Selnoflast	DM4NKNK	Phase 1	Small molecule	[54]
GSK269962A	DM5I2HL	Clinical trial	Small molecular drug	[55]
------------------------------------------------------------------------------------


⏷ Show the Full List of 36 Drug(s)

This Disease is Treated as An Indication in 17 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amidine compound 1	DMUPT9A	Patented	Small molecular drug	[56]
Amidine compound 2	DM2UWSX	Patented	Small molecular drug	[56]
Amidine compound 3	DMV0QJ4	Patented	Small molecular drug	[56]
Amidine compound 4	DM9EGVN	Patented	Small molecular drug	[56]
Amidine compound 5	DMMN8OY	Patented	Small molecular drug	[56]
Amidine compound 6	DMFNK0L	Patented	Small molecular drug	[56]
Complex heterocyclic compound 1	DMWYJF6	Patented	Small molecular drug	[57]
Imidazopyridazine derivative 3	DMXVOP3	Patented	Small molecular drug	[56]
Imidazopyridazine derivative 4	DMIAJMO	Patented	Small molecular drug	[56]
Imidazopyridazine derivative 5	DM9SXYH	Patented	Small molecular drug	[56]
Imidazopyridazine derivative 6	DM5F1LR	Patented	Small molecular drug	[56]
Imidazopyridazine derivative 7	DM5X160	Patented	Small molecular drug	[56]
Imidazopyridazine derivative 8	DMF7NXJ	Patented	Small molecular drug	[56]
Piperazine urea derivative 3	DMNAJWQ	Patented	Small molecular drug	[56]
Piperazine urea derivative 4	DM3K7IM	Patented	Small molecular drug	[56]
Piperidine derivative 2	DMHXMB4	Patented	Small molecular drug	[56]
Piperidine derivative 3	DM80XRM	Patented	Small molecular drug	[56]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 Drug(s)

This Disease is Treated as An Indication in 63 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Azapropazone	DMDSL4E	Withdrawn from market	Small molecular drug	[1]
Benoxaprofen	DM5ZOX8	Withdrawn from market	Small molecular drug	[58]
Droxicam	DMRZ5D7	Withdrawn from market	Small molecular drug	[59]
Bermoprofen	DM7BN1A	Discontinued in Preregistration	Small molecular drug	[60]
Pirazolac	DMP6BG4	Discontinued in Preregistration	Small molecular drug	[61]
PRINOMIDE TROMETHAMINE	DMI02PF	Discontinued in Phase 3	Small molecular drug	[62]
TILNOPROFEN ARBAMEL	DMAN0OZ	Discontinued in Phase 3	Small molecular drug	[63]
AA-2379	DM78623	Discontinued in Phase 2	Small molecular drug	[64]
CRx-102	DMCD8LN	Discontinued in Phase 2	NA	[65]
OPM-3023	DMVM4NE	Discontinued in Phase 2	NA	[66]
T487	DMZTL7H	Discontinued in Phase 2	Small molecular drug	[67]
TAK-661	DM92IHF	Discontinued in Phase 2	NA	[68]
BAY-Y-1015	DM0UEKF	Discontinued in Phase 1	NA	[69]
BXL-746	DMUD6IK	Discontinued in Phase 1	NA	[70]
FLM-5011	DMKWTPX	Discontinued in Phase 1	Small molecular drug	[71]
KW-6055	DM76O23	Discontinued in Phase 1	Small molecular drug	[72]
MED-27	DMFLDUN	Discontinued in Phase 1	Small molecular drug	[73]
NPC-15669	DMOMVW9	Discontinued in Phase 1	Small molecular drug	[74]
PF-4308515	DM0787W	Discontinued in Phase 1	Small molecular drug	[75]
PS386113	DM73AH5	Discontinued in Phase 1	NA	[76]
TA-5493	DMFES2K	Discontinued in Phase 1	NA	[77]
V85546	DMLFMSY	Discontinued in Phase 1	NA	[78]
A-252444.0	DMDTA36	Terminated	NA	[88]
A-80263	DM89BGE	Terminated	NA	[89]
AMG-548	DMYIPLH	Terminated	Small molecular drug	[90]
ATLIPROFEN METHYL ESTER	DMS2FB3	Terminated	Small molecular drug	[91]
BE-16627B	DM1SVQX	Terminated	Small molecular drug	[92]
BF-388	DMTJBPR	Terminated	Small molecular drug	[93]
BN-58705	DM9O3I5	Terminated	Small molecular drug	[94]
BW755C	DMQM3P4	Terminated	Small molecular drug	[95]
CDE-5110	DMGQ9WP	Terminated	NA	[96]
CDE-6960	DMA0DKI	Terminated	NA	[97]
CGS-26529	DMJ4FGZ	Terminated	NA	[98]
CGS-32359	DM1VZ2I	Terminated	NA	[99]
CMI-206	DMEIW7K	Terminated	NA	[100]
CY-9652	DMPBCLA	Terminated	NA	[101]
D-20450	DMLI3CL	Terminated	NA	[102]
D-21151	DM7TXML	Terminated	Small molecular drug	[103]
E-5110	DMR861Q	Terminated	Small molecular drug	[104]
EK-399	DMIP8NB	Terminated	Small molecular drug	[105]
ER-34122	DMAZVUB	Terminated	Small molecular drug	[106]
Florifenine	DMDVAI5	Terminated	Small molecular drug	[107]
FR-172357	DMY1LRI	Terminated	NA	[108]
GI-129471	DMXVP13	Terminated	Small molecular drug	[109]
GM-7050	DMEVIP9	Terminated	NA	[110]
IPL-423	DMMGS1W	Terminated	NA	[111]
Irindalone	DMJ3ZUN	Terminated	Small molecular drug	[112]
LEX-028	DMEGJ84	Terminated	NA	[113]
LY-243062	DMIDK36	Terminated	NA	[114]
Mdl 101,146	DMRSOBG	Terminated	Small molecular drug	[115]
NMI-102	DM870SX	Terminated	NA	[116]
NMI-1182	DM5IFU9	Terminated	Small molecular drug	[117]
PBI-1101	DMWD1RC	Terminated	NA	[118]
Ro-25-4094	DMVB0C3	Terminated	Small molecular drug	[119]
Ro-31-8830	DMTIW6K	Terminated	Small molecular drug	[120]
RP-66364	DM6HJX7	Terminated	NA	[121]
RP-69698	DMUY4FD	Terminated	Small molecular drug	[122]
S-14080	DM759KX	Terminated	NA	[123]
SB-282241	DMZLKCF	Terminated	Small molecular drug	[124]
ST-570	DMC4X59	Terminated	Small molecular drug	[125]
Trifenagrel	DMI7YPL	Terminated	Small molecular drug	[126]
UK-78282	DMKBILF	Terminated	Small molecular drug	[127]
Vapaliximab	DM73EPK	Terminated	Antibody	[128]
------------------------------------------------------------------------------------


⏷ Show the Full List of 63 Drug(s)

This Disease is Treated as An Indication in 11 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BC-1215	DM3EUBA	Preclinical	Small molecular drug	[79]
CF502	DMQSJ20	Preclinical	Small molecular drug	[80]
CF602	DM0ULO2	Preclinical	Small molecular drug	[81]
COR100140	DMN0GTR	Preclinical	Small molecular drug	[82]
GNE684	DMXVHOQ	Preclinical	Small molecular drug	[83]
GSK4112	DM1S5UO	Preclinical	Small molecular drug	[84]
ML364	DM6RFLE	Preclinical	Small molecular drug	[85]
MS012	DM5AMFV	Preclinical	Small molecular drug	[86]
P22077	DMD8JIC	Preclinical	Small molecular drug	[87]
Spautin 1	DMJHWYP	Preclinical	Small molecular drug	[85]
vialinin A	DM95VQ6	Preclinical	Small molecular drug	[85]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 Drug(s)

This Disease is Treated as An Indication in 121 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ADC-1001	DMZJZC4	Investigative	NA	[129]
AF-3485	DM6WS8W	Investigative	NA	[129]
AG-NDP803	DMW9JSI	Investigative	NA	[129]
ALD-701	DM1S6V2	Investigative	NA	[129]
AMG-247	DMU6WR9	Investigative	NA	[130]
AMG-327	DMYSL3X	Investigative	NA	[129]
AP-401	DMOXFXK	Investigative	NA	[129]
APG-103	DMR93WE	Investigative	NA	[131]
API-003	DMBR8RS	Investigative	NA	[129]
AR-XYZ	DMWHUKZ	Investigative	NA	[132]
ATX-3105	DMQALXE	Investigative	NA	[129]
AW-814141	DMIGDUC	Investigative	NA	[129]
AZ-11657312	DMRUA0Y	Investigative	NA	[133]
BF/PC-18	DMOQEZK	Investigative	NA	[134]
BF/PC-21	DMCWB1V	Investigative	NA	[135]
BLX-1017	DM7HD13	Investigative	NA	[129]
BM-162115	DMDNPML	Investigative	Small molecular drug	[136]
BMS-488516	DM6Y1QF	Investigative	NA	[137]
BMS-509744	DMGH1LX	Investigative	Small molecular drug	[137]
BMS-A	DMI796T	Investigative	Small molecular drug	[138]
BYK-191023	DMAWMDN	Investigative	Small molecular drug	[139]
C5aR pepducins	DMEK4HZ	Investigative	NA	[140]
Carotegrast	DM9XRS3	Investigative	Small molecular drug	[129]
CAT-1000	DMIWGIK	Investigative	NA	[129]
CAT-4000	DM40SLQ	Investigative	NA	[129]
CEP-37248	DMLHASK	Investigative	NA	[129]
CG-023132	DMGY2PM	Investigative	NA	[129]
CGEN-855	DM4FMPJ	Investigative	NA	[141]
CGEN-913	DMX2JGP	Investigative	NA	[129]
CGEN-920	DMPXHP5	Investigative	NA	[129]
CHR-3620	DMRCA7R	Investigative	NA	[129]
CR-4174	DM3M5AW	Investigative	NA	[142]
CSL-324	DMTN1P2	Investigative	Antibody	[143]
CT-112	DMO4ZR5	Investigative	Small molecular drug	[129]
CZC-19091	DMYBL5G	Investigative	NA	[144]
DP-802	DMARTC2	Investigative	NA	[145]
EC-0746	DM478FF	Investigative	NA	[129]
EC-0845	DMK6E10	Investigative	NA	[146]
EM-703	DM8CXI8	Investigative	NA	[129]
Endomorphins	DMI2RQS	Investigative	NA	[147]
ERB-002	DMYRDBX	Investigative	NA	[148]
ESN-YY	DMPMWA4	Investigative	NA	[129]
FM-401	DMUHLRU	Investigative	NA	[129]
FP-1302	DMHEUD7	Investigative	NA	[129]
FX-141L	DMRH53O	Investigative	NA	[129]
FX-300	DMFMAQR	Investigative	NA	[129]
FX-87L	DMSC41A	Investigative	NA	[129]
GL-4001	DMRT9MA	Investigative	NA	[129]
Glucocorticoid mimetics	DMLDS6X	Investigative	NA	[129]
Glycanics	DM9L1QK	Investigative	NA	[129]
Glycosaminoglycans	DMDXCYH	Investigative	NA	[129]
GSK-0862	DM7B4RG	Investigative	NA	[129]
GSK-280	DM325YR	Investigative	NA	[145]
HC-030031	DMOY2AI	Investigative	Small molecular drug	[149]
HE-3177	DMSOIWV	Investigative	NA	[129]
IDDBCP226234	DMBFX5H	Investigative	NA	[150]
IMMLG-5521	DM606EG	Investigative	NA	[129]
INCB-10820	DMZCHSD	Investigative	NA	[138]
INV-311	DM8BZVI	Investigative	NA	[151]
IRX-01	DMDG2KX	Investigative	NA	[129]
JI-3292	DML1C98	Investigative	NA	[129]
KD-7332	DMJ2X64	Investigative	NA	[139]
KDT-500	DM3HI3H	Investigative	Small molecular drug	[129]
KRH-102140	DM9XRV5	Investigative	NA	[129]
LASSBio-1524	DMP7PLN	Investigative	Small molecular drug	[129]
LD201t1	DMC5XQ6	Investigative	Aptamer	[152]
Maclizumab	DMMEQTJ	Investigative	Monoclonal antibody	[129]
MEDI-541	DMW5XNK	Investigative	NA	[129]
MK-2894	DMP4Q0J	Investigative	Small molecular drug	[153]
MK-5286	DMOL4Z3	Investigative	NA	[129]
MK-7285	DMVEEP9	Investigative	NA	[129]
MOR-104	DMCP2T5	Investigative	NA	[129]
MOR-105	DM0V44J	Investigative	NA	[129]
MT-204	DMS4M5U	Investigative	NA	[129]
Mucin type glycoproteins	DMUQQ1S	Investigative	NA	[129]
Multiform PI3K inhibitors	DMW2Z4I	Investigative	NA	[154]
Myrrhanol A	DMCVRPI	Investigative	Small molecular drug	[129]
ND-07	DM92WA6	Investigative	NA	[129]
Norisoboldine	DMKWE2D	Investigative	Small molecular drug	[129]
Nov-038	DMGI5NG	Investigative	NA	[129]
NOX-D14	DMVADCY	Investigative	NA	[129]
OCID-2987	DM69O3S	Investigative	NA	[155]
Oleuropein	DMTDOL8	Investigative	Small molecular drug	[129]
OPN-302	DM1KO1A	Investigative	NA	[129]
OPN-401	DMD8BWG	Investigative	NA	[129]
OX-MPI	DMX4H8E	Investigative	NA	[129]
P-979	DM4Z0QV	Investigative	Small molecular drug	[129]
PARCETASAL	DMWVPSM	Investigative	Small molecular drug	[156]
PD-156	DMY5SX9	Investigative	NA	[157]
PF-04957325	DMPEZKT	Investigative	NA	[158]
PF-05313261	DMOLI1E	Investigative	NA	[159]
PF-4957325-00	DMV4P7S	Investigative	NA	[160]
PF-956980	DMIUZSR	Investigative	Small molecular drug	[161]
PK68	DMIUZGY	Investigative	Small molecular drug	[162]
PTS-508a	DM0G2XX	Investigative	NA	[129]
RQ-00000008	DMP9V7U	Investigative	Small molecular drug	[163]
RTA-403 analog	DMYVGCL	Investigative	NA	[129]
SA-6541	DMVA5FE	Investigative	Small molecular drug	[164]
SB-612111	DM2SZ3F	Investigative	Small molecular drug	[165]
Sch-900875	DM346KA	Investigative	NA	[166]
SD-281	DMN1KTA	Investigative	NA	[129]
SEL-100130	DMQP5OR	Investigative	NA	[129]
SF-110	DMZ0KEK	Investigative	NA	[129]
SK-126	DM8EBMH	Investigative	NA	[129]
SKLB-010	DMUVAFO	Investigative	NA	[139]
SUN-13333	DMFUDBU	Investigative	NA	[129]
TA-101	DMOFTH1	Investigative	NA	[129]
TCK-1	DM0EIQP	Investigative	NA	[129]
Thiolated chitosan nanoparticle theophylline	DMP4XMV	Investigative	NA	[129]
UCB-1277763	DMFUE43	Investigative	NA	[145]
UK-387618	DMW0QFC	Investigative	NA	[129]
UR-13756	DMXNMF8	Investigative	NA	[129]
VT-224	DMB7I0A	Investigative	NA	[167]
VT-310	DM1QBXM	Investigative	NA	[168]
VT-346	DM3CTVF	Investigative	NA	[129]
VT-384	DMIWNJW	Investigative	NA	[129]
VX-467	DM4Q5DO	Investigative	NA	[161]
XPro-1595	DMF8PFB	Investigative	NA	[129]
ZP-002	DMH6BT0	Investigative	NA	[129]
[3H]CGS8216	DMLP68J	Investigative	Small molecular drug	[169]
[3H]JNJ 7777120	DMZT8UD	Investigative	Small molecular drug	[170]
------------------------------------------------------------------------------------


⏷ Show the Full List of 121 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 73 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
UBA1	OTDDTGWK	No Known	Unknown	[171]
ADA2	OTGCV24S	Limited	Biomarker	[210]
AP1S3	OTPCMV24	Limited	Biomarker	[211]
AQP4	OTA9MYD5	Limited	Biomarker	[212]
ARC	OTN2QQPG	Limited	Genetic Variation	[213]
ARHGEF28	OT3F32IU	Limited	Biomarker	[214]
ARID5A	OTQT7CG9	Limited	Biomarker	[215]
ATOX1	OT05LF59	Limited	Biomarker	[216]
BFAR	OTTBG0V7	Limited	Biomarker	[217]
BHMT	OTYB6PXZ	Limited	Altered Expression	[218]
BLOC1S4	OTDCFUJC	Limited	Biomarker	[219]
C5AR2	OTP1Q82J	Limited	Biomarker	[220]
CACUL1	OT6P1ZVP	Limited	Biomarker	[221]
CASP12	OTY2W6FG	Limited	Biomarker	[222]
CNBP	OTTGM9NK	Limited	Altered Expression	[223]
DUSP26	OTI7WIYN	Limited	Biomarker	[224]
GPR15	OTK8674M	Limited	Genetic Variation	[225]
GPR65	OTCF5O4G	Limited	Altered Expression	[226]
KLRB1	OTQ2959Y	Limited	Altered Expression	[227]
KNTC1	OTI2OOFN	Limited	Biomarker	[228]
LACC1	OT4SBHI8	Limited	Genetic Variation	[229]
LRCH4	OTJFA4AV	Limited	Biomarker	[230]
MTG1	OTC9U1LI	Limited	Biomarker	[231]
MUC13	OTWKS9MF	Limited	Altered Expression	[232]
NCSTN	OT5QBTA4	Limited	Biomarker	[233]
NLRC4	OTAIA3NA	Limited	Biomarker	[207]
POP1	OTBIYMJ0	Limited	Biomarker	[234]
PRELP	OT9EEBUJ	Limited	Biomarker	[235]
PROP1	OT8GF6N8	Limited	Biomarker	[236]
RAB11A	OTC4FW0J	Limited	Biomarker	[237]
RAB11FIP2	OTTX9RWE	Limited	Biomarker	[237]
SDC3	OT1P0LJM	Limited	Biomarker	[238]
STEAP4	OTFTLAEZ	Limited	Altered Expression	[239]
STK24	OTGUHOIL	Limited	Biomarker	[240]
TAGAP	OTHJNNO2	Limited	Biomarker	[241]
TRAF4	OTJLRVMC	Limited	Biomarker	[216]
TREX1	OTQG7K12	Limited	Biomarker	[242]
RIPK3	OTL1D484	Disputed	Biomarker	[243]
ATG16L1	OTEOYC5D	moderate	Genetic Variation	[244]
CIITA	OTRJNZFO	moderate	Biomarker	[245]
IFRD1	OT4SQMLQ	moderate	Biomarker	[246]
IRGM	OTKD3O5Z	moderate	Biomarker	[247]
LPIN2	OTRRTMXX	moderate	Genetic Variation	[248]
NR2C2	OTDZWVOJ	moderate	Genetic Variation	[182]
PIK3R5	OT4LNXJU	moderate	Biomarker	[249]
SAMHD1	OTBCIBC7	moderate	Genetic Variation	[250]
ACKR4	OTZPWT2N	Strong	Altered Expression	[251]
ACTR2	OT3C8U5T	Strong	Genetic Variation	[252]
ANGPTL2	OTB6JG41	Strong	Genetic Variation	[252]
ANO2	OT650E98	Strong	Altered Expression	[253]
ARPC1B	OTYE3DN2	Strong	Genetic Variation	[252]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[254]
BTNL2	OTTTEMZA	Strong	Biomarker	[255]
CCR10	OT7ZWSSD	Strong	Biomarker	[256]
CD5L	OTPY4WQR	Strong	Biomarker	[257]
ECM1	OT1K65VW	Strong	Biomarker	[258]
HYAL2	OTTVINXW	Strong	Biomarker	[259]
IL22RA2	OTGOFDCY	Strong	Altered Expression	[260]
IL36RN	OT5CO95A	Strong	Biomarker	[261]
MEFV	OTRJ6S6K	Strong	Biomarker	[262]
NAIP	OTLA925F	Strong	Biomarker	[207]
PDZD2	OTPPVRGY	Strong	Biomarker	[263]
PHB2	OTCAX3AW	Strong	Biomarker	[264]
PLD4	OT5I74II	Strong	Biomarker	[265]
PSTPIP2	OTG6F93V	Strong	Biomarker	[266]
RETREG1	OTYOSLZX	Strong	Biomarker	[267]
RHOF	OTPA3F8Q	Strong	Altered Expression	[268]
RTL1	OTOT33IM	Strong	Biomarker	[269]
SEMA3F	OTQFMS8S	Strong	Altered Expression	[270]
SEMA7A	OT0ZJK64	Strong	Biomarker	[271]
SETMAR	OTE2MIMZ	Strong	Biomarker	[269]
SHARPIN	OTU1J2KH	Strong	Genetic Variation	[272]
CARTPT	OTTE4V9S	Definitive	Altered Expression	[273]
------------------------------------------------------------------------------------


⏷ Show the Full List of 73 DOT(s)

This Disease Is Related to 38 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
UBA1	TTXHWA7	No Known	Unknown	[171]
AMD1	TTBFROQ	Limited	Biomarker	[172]
CCR9	TTIPS8B	Limited	Biomarker	[173]
GLRX	TTRJCNG	Limited	Biomarker	[174]
GP6	TTTJUVZ	Limited	Biomarker	[175]
HDAC7	TTMUEK1	Limited	Biomarker	[176]
HDC	TTV9GOF	Limited	Biomarker	[177]
IL19	TT87RWS	Limited	Biomarker	[178]
IL37	TTQTX98	Limited	Altered Expression	[179]
MANF	TT56RYE	Limited	Altered Expression	[180]
MAP3K6	TT64GC2	Limited	Genetic Variation	[181]
MAP3K7	TTJQT60	Limited	Genetic Variation	[182]
MSRB1	TT1QUZV	Limited	Biomarker	[183]
MYLK	TT18ETS	Limited	Biomarker	[184]
PSMB10	TTPNACM	Limited	Altered Expression	[185]
RBCK1	TTIKUVC	Limited	Genetic Variation	[186]
RHD	TTLCKI8	Limited	Biomarker	[187]
RIPK2	TTCQ2E5	Limited	Biomarker	[188]
CCL23	TTHAPJK	moderate	Biomarker	[189]
FFAR2	TT0FYAN	moderate	Biomarker	[190]
ITCH	TT5SEWD	moderate	Biomarker	[191]
OPRL1	TTNT7K8	moderate	Biomarker	[192]
PTPN6	TT369M5	moderate	Genetic Variation	[193]
TNFRSF18	TTG6LA7	moderate	Altered Expression	[194]
B2M	TTY7FKA	Strong	Biomarker	[195]
CSF3R	TTC70AJ	Strong	Biomarker	[196]
ERAP1	TT60XFL	Strong	Biomarker	[197]
GAP43	TTSGLN5	Strong	Altered Expression	[198]
GBA	TT1B5PU	Strong	Biomarker	[199]
LTBR	TTFO0PM	Strong	Biomarker	[200]
MAP3K8	TTGECUM	Strong	Biomarker	[201]
MAPKAPK2	TTMUG9D	Strong	Altered Expression	[202]
NOD2	TTYPUHA	Strong	Genetic Variation	[203]
NR0B2	TT25A9Q	Strong	Genetic Variation	[181]
RIPK1	TTVJHX8	Strong	Altered Expression	[83]
S100A12	TTQ4ESF	Strong	Biomarker	[204]
XDH	TT7RJY8	Strong	Biomarker	[205]
IDO2	TTALN9W	Definitive	Biomarker	[206]
------------------------------------------------------------------------------------


⏷ Show the Full List of 38 DTT(s)

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC11	DTWN7FC	Limited	Biomarker	[207]
ABCD2	DT4MBHD	moderate	Biomarker	[208]
ABCD1	DTKM9DZ	Strong	Biomarker	[208]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GANAB	DEMWKYT	Limited	Biomarker	[209]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7060).
4	Atorvastatin FDA Label
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7061).
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7131).
7	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7067).
9	Exenatide FDA Label
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7077).
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7078).
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7606).
13	Folic acid FDA Label
14	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010554.
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2868).
16	Tolerability of imidazole salycilate in aspirin-sensitive patients. Allergy Proc. 1995 Sep-Oct;16(5):251-4.
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4968).
18	Methotrexate FDA Label
19	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012772.
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7605).
21	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7096).
22	Triamcinolone FDA Label
23	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
24	Clinical pipeline report, company report or official report of Merck.
25	FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
26	ClinicalTrials.gov (NCT00541489) Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip. U.S. National Institutes of Health.
27	Clinical pipeline report, company report or official report of Biotie.
28	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6059).
29	ClinicalTrials.gov (NCT00447837) Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis. U.S. National Institutes of Health.
30	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014340)
31	Clinical pipeline report, company report or official report of SciClone.
32	ClinicalTrials.gov (NCT01107236) Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction. U.S. National Institutes of Health.
33	ClinicalTrials.gov (NCT02444910) Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects. U.S. National Institutes of Health.
34	Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7.
35	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001904)
36	PCT-233, a novel modulator of pro- and anti-inflammatory cytokine production. Clin Exp Immunol. 2004 Mar;135(3):440-7.
37	Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost. 2004 Jul;92(1):191-200.
38	Clinical pipeline report, company report or official report of Vectura.
39	Clinical pipeline report, company report or official report of Zydus-Cadila Group.
40	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029529)
41	ClinicalTrials.gov (NCT05662033) A Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Ascending Doses in Healthy Subjects, an Open-label Study to Assess the Relative Bioavailability and Food Effect of a Tablet Formulation of AZD6793 in Healthy Subjects and a Blinded, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Tablet Formulation of AZD6793 in Patients With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
42	ClinicalTrials.gov (NCT01934101) Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers. U.S. National Institutes of Health.
43	Biologics Research Pushing Frontiers of Science With More Than 900 Medicines and Vaccines in Development. Pharmaceutical Research and Manufacturers of America report. 2013.
44	ClinicalTrials.gov (NCT00924105) Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
45	Clinical pipeline report, company report or official report of Gilead
46	Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod. 2004 Aug;67(8):1216-38.
47	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
48	Mistral Pharma Announces Phase I Results from a Pilot PK Study on MIST-B03. Mistral Pharma Inc. 2007-07-20.
49	ClinicalTrials.gov (NCT01339156) Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain. U.S. National Institutes of Health.
50	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018363)
51	An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Front Pharmacol. 2022 Nov 16;13:1037983.
52	Clinical pipeline report, company report or official report of Sanofi
53	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026396)
54	Clinical pipeline report, company report or official report of Roche
55	Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
56	Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
57	Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
58	Benoxaprofen: side-effect profile in 300 patients. Br Med J (Clin Res Ed). 1982 May 8;284(6326):1365-8.
59	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003115)
60	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000932)
61	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000980)
62	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000017)
63	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003086)
64	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000920)
65	ClinicalTrials.gov (NCT00521989) CRx-102 Osteoarthritis Multicenter Evaluation Trial. U.S. National Institutes of Health.
66	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030958)
67	Clinical pipeline report, company report or official report of ChemoCentryx.
68	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010829)
69	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005124)
70	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025073)
71	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002782)
72	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000699)
73	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003396)
74	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001544)
75	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031569)
76	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026075)
77	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022792)
78	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020392)
79	Targeting F box protein Fbxo3 to control cytokine-driven inflammation. J Immunol. 2013 Nov 15;191(10):5247-55.
80	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5601).
81	2011 Pipeline of Can-Fite BioPharm.
82	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020117)
83	RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ. 2020 Jan;27(1):161-175.
84	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
85	Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78.
86	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
87	P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6. Aging (Albany NY). 2020 Jun 9;12(11):10969-10982.
88	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012566)
89	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003607)
90	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019881)
91	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000964)
92	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006074)
93	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003689)
94	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005955)
95	BW755C, a dual lipoxygenase/cyclooxygenase inhibitor, reduces mural platelet and neutrophil deposition and vasoconstriction after angioplasty injury in pigs. J Pharmacol Exp Ther. 1996 Apr;277(1):17-21.
96	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025959)
97	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
98	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005833)
99	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010131)
100	Cmi206: A potent dual platelet activating factor antagonist and 5-lipoxygenase inhibitor. Bioorganic & Medicinal Chemistry Letters. 03/1995; 5(6):643-648.
101	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006649)
102	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003821)
103	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003222)
104	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000953)
105	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004080)
106	Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 2002 Jan;91(1):258-66.
107	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003826)
108	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008533)
109	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006709)
110	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005329)
111	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012693)
112	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000378)
113	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007321)
114	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005079)
115	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007771)
116	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009182)
117	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020060)
118	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018032)
119	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005401)
120	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001273)
121	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003795)
122	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003683)
123	S14080, a peripheral analgesic acting by release of an endogenous circulating opioid-like substance. Br J Pharmacol. 1995 Jan;114(2):303-8.
124	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 782).
125	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003187)
126	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000448)
127	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009179)
128	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017603)
129	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
130	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
131	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
132	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
133	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484).
134	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
135	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350).
136	Investigation on the effect of experimental phospholipase A2 inhibitors on the formyl-methionyl-leucyl-phenylalanine-stimulated chemotaxis of human leukocytes in vitro. Arzneimittelforschung. 1998 Jan;48(1):77-81.
137	Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3.
138	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
139	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1250).
140	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 32).
141	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6241).
142	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
143	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
144	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
145	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499).
146	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
147	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
148	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621).
149	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4211).
150	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2159).
151	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2789).
152	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
153	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5856).
154	Exploring the potential of PI3K inhibitors for inflammation and cancer. Biochem Soc Trans. 2007 Apr;35(Pt 2):253-6.
155	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
156	Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase. J Neurosci Res. 2003 Mar 15;71(6):844-52.
157	Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
158	Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation.Front Pharmacol. 2016 Aug 23;7:259.
159	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045).
160	PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS One. 2010 Aug 9;5(8):e12011.
161	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
162	Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019 Jun 24;10(7):493.
163	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5857).
164	Synthesis and biological evaluation of N-mercaptoacylcysteine derivatives as leukotriene A4 hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):442-6.
165	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1693).
166	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 70).
167	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 67).
168	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900).
169	Substituted 3-(2-benzoxazyl)-benzimidazol-2-(1H)-ones: a new class of GABA(A) brain receptor ligands. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2723-6.
170	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1278).
171	Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
172	Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis.Invest Ophthalmol Vis Sci. 2019 Aug 1;60(10):3520-3526. doi: 10.1167/iovs.18-26444.
173	CCR9 Expressing T Helper and T Follicular Helper Cells Exhibit Site-Specific Identities During Inflammatory Disease.Front Immunol. 2019 Jan 4;9:2899. doi: 10.3389/fimmu.2018.02899. eCollection 2018.
174	Novel chloroacetamido compound CWR-J02 is an anti-inflammatory glutaredoxin-1 inhibitor.PLoS One. 2017 Nov 20;12(11):e0187991. doi: 10.1371/journal.pone.0187991. eCollection 2017.
175	Imaging fibrosis in inflammatory diseases: targeting the exposed extracellular matrix.Theranostics. 2019 Apr 13;9(10):2868-2881. doi: 10.7150/thno.28892. eCollection 2019.
176	Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages.J Biol Chem. 2013 Aug 30;288(35):25362-25374. doi: 10.1074/jbc.M113.496281. Epub 2013 Jul 12.
177	Repurposing a Histamine Detection Platform for High-Throughput Screening of Histidine Decarboxylase.SLAS Discov. 2018 Oct;23(9):974-981. doi: 10.1177/2472555218778053. Epub 2018 Jun 8.
178	IL-19 and Other IL-20 Family Member Cytokines in Vascular Inflammatory Diseases.Front Immunol. 2018 Apr 6;9:700. doi: 10.3389/fimmu.2018.00700. eCollection 2018.
179	Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris.Iran J Allergy Asthma Immunol. 2018 Apr;17(2):179-187.
180	Mesencephalic astrocyte-derived neurotrophic factor is involved in inflammation by negatively regulating the NF-B pathway.Sci Rep. 2015 Feb 2;5:8133. doi: 10.1038/srep08133.
181	ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis.J Clin Invest. 2018 May 1;128(5):2042-2047. doi: 10.1172/JCI98446. Epub 2018 Apr 9.
182	Distinct IL-1-responsive enhancers promote acute and coordinated changes in chromatin topology in a hierarchical manner.EMBO J. 2020 Jan 2;39(1):e101533. doi: 10.15252/embj.2019101533. Epub 2019 Nov 7.
183	Selenoprotein MsrB1 promotes anti-inflammatory cytokine gene expression in macrophages and controls immune response in vivo.Sci Rep. 2017 Jul 11;7(1):5119. doi: 10.1038/s41598-017-05230-2.
184	Myosin Light Chain Kinase: A Potential Target for Treatment of Inflammatory Diseases.Front Pharmacol. 2017 May 23;8:292. doi: 10.3389/fphar.2017.00292. eCollection 2017.
185	Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).J Med Chem. 2018 Dec 27;61(24):11127-11143. doi: 10.1021/acs.jmedchem.8b01201. Epub 2018 Dec 11.
186	LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis.Nature. 2018 May;557(7703):112-117. doi: 10.1038/s41586-018-0064-8. Epub 2018 Apr 25.
187	Influence of cytokine gene polymorphism on the risk of rheumatic heart disease - A meta-analysis.Immunol Lett. 2018 Feb;194:69-78. doi: 10.1016/j.imlet.2018.01.001. Epub 2018 Jan 6.
188	RIP2 promotes FcR-mediated reactive oxygen species production.J Biol Chem. 2019 Jun 28;294(26):10365-10378. doi: 10.1074/jbc.RA118.007218. Epub 2019 May 21.
189	Potential involvement of CCL23 in atherosclerotic lesion formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes.Inflamm Res. 2011 Sep;60(9):889-95. doi: 10.1007/s00011-011-0350-5. Epub 2011 Jun 9.
190	N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model. Bioorg Med Chem. 2018 Oct 1; 26(18):5169-5180.
191	ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways.Curr Biol. 2009 Aug 11;19(15):1255-63. doi: 10.1016/j.cub.2009.06.038. Epub 2009 Jul 9.
192	Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes.J Neuroimmune Pharmacol. 2008 Jun;3(2):75-82. doi: 10.1007/s11481-007-9086-y. Epub 2007 Sep 15.
193	Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.Nat Immunol. 2020 Jan;21(1):54-64. doi: 10.1038/s41590-019-0550-7. Epub 2019 Dec 9.
194	Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages.Mol Immunol. 2008 Jan;45(2):523-33. doi: 10.1016/j.molimm.2007.05.013. Epub 2007 Jun 28.
195	Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.Eur Cytokine Netw. 1998 Jun;9(2):161-70.
196	Therapeutic Targeting of the G-CSF Receptor Reduces Neutrophil Trafficking and Joint Inflammation in Antibody-Mediated Inflammatory Arthritis.J Immunol. 2016 Dec 1;197(11):4392-4402. doi: 10.4049/jimmunol.1600121. Epub 2016 Nov 2.
197	Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Polymorphism Relevant to Inflammatory Disease Shapes the Peptidome of the Birdshot Chorioretinopathy-Associated HLA-A*29:02 Antigen.Mol Cell Proteomics. 2015 Jul;14(7):1770-80. doi: 10.1074/mcp.M115.048959. Epub 2015 Apr 19.
198	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.Sci Rep. 2019 Nov 21;9(1):17309. doi: 10.1038/s41598-019-54032-1.
199	Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease.PLoS One. 2015 Aug 27;10(8):e0136633. doi: 10.1371/journal.pone.0136633. eCollection 2015.
200	Association of LTR gene polymorphisms with prostate volume in benign prostatic hyperplasia in the Korean population.Genet Mol Res. 2015 Dec 29;14(4):18607-15. doi: 10.4238/2015.December.28.9.
201	The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation.Sci Signal. 2017 Apr 18;10(475):eaah4273. doi: 10.1126/scisignal.aah4273.
202	Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2.J Immunol. 2006 Feb 1;176(3):1431-8. doi: 10.4049/jimmunol.176.3.1431.
203	Enhancement of Muramyl Dipeptide-Dependent NOD2 Activity by a Self-Derived Peptide.J Cell Biochem. 2017 May;118(5):1227-1238. doi: 10.1002/jcb.25778. Epub 2017 Jan 10.
204	S100 Calgranulins in inflammatory arthritis.Immunol Cell Biol. 2010 Jan;88(1):41-9. doi: 10.1038/icb.2009.88. Epub 2009 Nov 24.
205	Diminishing Inflammation by Reducing Oxidant Generation: Nitrated Fatty Acid-Mediated Inactivation of Xanthine Oxidoreductase.Adv Exp Med Biol. 2019;1127:59-65. doi: 10.1007/978-3-030-11488-6_4.
206	Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28.
207	NAIP/NLRC4 inflammasome activation in MRP8(+) cells is sufficient to cause systemic inflammatory disease.Nat Commun. 2017 Dec 20;8(1):2209. doi: 10.1038/s41467-017-02266-w.
208	Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.J Lipid Res. 2009 Jan;50(1):135-47. doi: 10.1194/jlr.M800321-JLR200. Epub 2008 Aug 21.
209	A Secreted Phospholipase A(2) Induces Formation of Smooth Muscle Foam Cells Which Transdifferentiate to Macrophage-Like State.Molecules. 2019 Sep 6;24(18):3244. doi: 10.3390/molecules24183244.
210	ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2019 Jan 14;9:2767. doi: 10.3389/fimmu.2018.02767. eCollection 2018.
211	Newly recognized Mendelian disorders with rheumatic manifestations.Curr Opin Rheumatol. 2015 Sep;27(5):511-9. doi: 10.1097/BOR.0000000000000207.
212	CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder.Ann Clin Transl Neurol. 2017 May 9;4(6):369-380. doi: 10.1002/acn3.418. eCollection 2017 Jun.
213	Systematic understanding of the mechanism and effects of Arctigenin attenuates inflammation in dextran sulfate sodium-induced acute colitis through suppression of NLRP3 inflammasome by SIRT1.Am J Transl Res. 2019 Jul 15;11(7):3992-4009. eCollection 2019.
214	RIP2 activity in inflammatory disease and implications for novel therapeutics.J Leukoc Biol. 2013 Nov;94(5):927-32. doi: 10.1189/jlb.0213109. Epub 2013 Jun 21.
215	A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression.Curr Pharm Des. 2018;24(16):1766-1771. doi: 10.2174/1381612824666180426103753.
216	Novel interaction of antioxidant-1 with TRAF4: role in inflammatory responses in endothelial cells.Am J Physiol Cell Physiol. 2019 Dec 1;317(6):C1161-C1171. doi: 10.1152/ajpcell.00264.2019. Epub 2019 Sep 25.
217	Antagonistic regulation of F-BAR protein assemblies controls actin polymerization during podosome formation.J Cell Sci. 2013 May 15;126(Pt 10):2267-78. doi: 10.1242/jcs.122515. Epub 2013 Mar 22.
218	Lean Body Mass Harbors Sensing Mechanisms that Allow Safeguarding of Methionine Homeostasis.Nutrients. 2017 Sep 20;9(9):1035. doi: 10.3390/nu9091035.
219	Mutation screening of the IL-1 receptor antagonist gene in chronic non-bacterial osteomyelitis of childhood and adolescence.Clin Exp Rheumatol. 2011 Nov-Dec;29(6):1040-3. Epub 2011 Dec 22.
220	C5L2: a controversial receptor of complement anaphylatoxin, C5a.FASEB J. 2013 Mar;27(3):855-64. doi: 10.1096/fj.12-220509. Epub 2012 Dec 13.
221	Stabilization of HIF through inhibition of Cullin-2 neddylation is protective in mucosal inflammatory responses.FASEB J. 2015 Jan;29(1):208-15. doi: 10.1096/fj.14-259663. Epub 2014 Oct 17.
222	CASPASE-12 and rheumatoid arthritis in African-Americans.Immunogenetics. 2014 Apr;66(4):281-5. doi: 10.1007/s00251-014-0762-9. Epub 2014 Feb 11.
223	Sensing danger through a "finger".J Exp Med. 2018 Dec 3;215(12):2969-2971. doi: 10.1084/jem.20182034. Epub 2018 Nov 20.
224	The Neurotoxin DSP-4 Induces Hyperalgesia in Rats that is Accompanied by Spinal Oxidative Stress and Cytokine Production.Neuroscience. 2018 Apr 15;376:13-23. doi: 10.1016/j.neuroscience.2018.01.058. Epub 2018 Feb 5.
225	Methylation of MTHFR Moderates the Effect of Smoking on Genomewide Methylation Among Middle Age African Americans.Front Genet. 2018 Dec 10;9:622. doi: 10.3389/fgene.2018.00622. eCollection 2018.
226	Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis.Nat Commun. 2017 Nov 15;8(1):1510. doi: 10.1038/s41467-017-01771-2.
227	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells.Front Immunol. 2018 Apr 9;9:486. doi: 10.3389/fimmu.2018.00486. eCollection 2018.
228	IgG4-related disease in the eye and ocular adnexa.Curr Opin Ophthalmol. 2017 Nov;28(6):617-622. doi: 10.1097/ICU.0000000000000427.
229	Human LACC1 increases innate receptor-induced responses and a LACC1 disease-risk variant modulates these outcomes.Nat Commun. 2017 Jun 8;8:15614. doi: 10.1038/ncomms15614.
230	Leucine-rich repeats and calponin homology containing 4 (Lrch4) regulates the innate immune response.J Biol Chem. 2019 Feb 8;294(6):1997-2008. doi: 10.1074/jbc.RA118.004300. Epub 2018 Dec 6.
231	Structure of natural variant transglutaminase 2 reveals molecular basis of gaining stability and higher activity.PLoS One. 2018 Oct 15;13(10):e0204707. doi: 10.1371/journal.pone.0204707. eCollection 2018.
232	MUC1 and MUC13 differentially regulate epithelial inflammation in response to inflammatory and infectious stimuli.Mucosal Immunol. 2013 May;6(3):557-68. doi: 10.1038/mi.2012.98. Epub 2012 Nov 14.
233	Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model.Front Immunol. 2018 Dec 14;9:2965. doi: 10.3389/fimmu.2018.02965. eCollection 2018.
234	The PYRIN Domain-only Protein POP1 Inhibits Inflammasome Assembly and Ameliorates Inflammatory Disease.Immunity. 2015 Aug 18;43(2):264-76. doi: 10.1016/j.immuni.2015.07.018. Epub 2015 Aug 11.
235	PRELP protein inhibits the formation of the complement membrane attack complex.J Biol Chem. 2012 Mar 9;287(11):8092-100. doi: 10.1074/jbc.M111.291476. Epub 2012 Jan 20.
236	(E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) Phenol Ameliorates MPTP-Induced Dopaminergic Neurodegeneration by Inhibiting the STAT3 Pathway.Int J Mol Sci. 2019 May 29;20(11):2632. doi: 10.3390/ijms20112632.
237	Rab11a Mediates Vascular Endothelial-Cadherin Recycling and Controls Endothelial Barrier Function.Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):339-49. doi: 10.1161/ATVBAHA.115.306549. Epub 2015 Dec 10.
238	Soluble syndecan-3 binds chemokines, reduces leukocyte migration in vitro and ameliorates disease severity in models of rheumatoid arthritis.Arthritis Res Ther. 2019 Jul 12;21(1):172. doi: 10.1186/s13075-019-1939-2.
239	Effect of Omega-3 Fatty Acid on STAMP2 Expression in the Heart and Kidney of 5/6 Nephrectomy Rat Model.Mar Drugs. 2018 Oct 23;16(11):398. doi: 10.3390/md16110398.
240	Protein Kinase Serine/Threonine Kinase 24 Positively Regulates Interleukin 17-Induced Inflammation by Promoting IKK Complex Activation.Front Immunol. 2018 Apr 30;9:921. doi: 10.3389/fimmu.2018.00921. eCollection 2018.
241	T cell activation Rho GTPase activating protein (TAGAP) is upregulated in clinical and experimental arthritis.Cytokine. 2018 Apr;104:130-135. doi: 10.1016/j.cyto.2017.10.002. Epub 2017 Oct 7.
242	Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5117-22. doi: 10.1073/pnas.1423804112. Epub 2015 Apr 6.
243	RIP3 deficiency exacerbates inflammation in dextran sodium sulfate-induced ulcerative colitis mice model.Cell Biochem Funct. 2017 Apr;35(3):156-163. doi: 10.1002/cbf.3257. Epub 2017 Mar 2.
244	An ATG16L1-dependent pathway promotes plasma membrane repair and limits Listeria monocytogenes cell-to-cell spread.Nat Microbiol. 2018 Dec;3(12):1472-1485. doi: 10.1038/s41564-018-0293-5. Epub 2018 Nov 26.
245	NOD-LRR proteins: role in host-microbial interactions and inflammatory disease.Annu Rev Biochem. 2005;74:355-83. doi: 10.1146/annurev.biochem.74.082803.133347.
246	Reduced expression of Tis7/IFRD1 protein in murine and human cystic fibrosis airway epithelial cell models homozygous for the F508del-CFTR mutation.Biochem Biophys Res Commun. 2011 Aug 5;411(3):471-6. doi: 10.1016/j.bbrc.2011.06.104. Epub 2011 Jun 24.
247	Role of autophagy and autophagy genes in inflammatory bowel disease.Curr Top Microbiol Immunol. 2009;335:141-67. doi: 10.1007/978-3-642-00302-8_7.
248	The lipin family: mutations and metabolism.Curr Opin Lipidol. 2009 Jun;20(3):165-70. doi: 10.1097/MOL.0b013e32832adee5.
249	Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea.J Rheumatol. 2005 Oct;32(10):1907-10.
250	SAMHD1 acts at stalled replication forks to prevent interferon induction.Nature. 2018 May;557(7703):57-61. doi: 10.1038/s41586-018-0050-1. Epub 2018 Apr 18.
251	Expression of CCX CKR in pulmonary sarcoidosis.Inflamm Res. 2006 Oct;55(10):441-5. doi: 10.1007/s00011-006-6019-9.
252	Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease.Nat Commun. 2017 Apr 3;8:14816. doi: 10.1038/ncomms14816.
253	Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16955-16960. doi: 10.1073/pnas.1902623116. Epub 2019 Aug 2.
254	Lack of association between single-nucleotide polymorphisms of pro- and anti-inflammatory cytokines and HTLV-1-associated myelopathy / tropical spastic paraparesis development in patients from Rio de Janeiro, Brazil.BMC Infect Dis. 2018 Nov 22;18(1):593. doi: 10.1186/s12879-018-3510-1.
255	BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation.J Immunol. 2007 Feb 1;178(3):1523-33. doi: 10.4049/jimmunol.178.3.1523.
256	Lymphatic precollectors contain a novel, specialized subpopulation of podoplanin low, CCL27-expressing lymphatic endothelial cells.Am J Pathol. 2008 Oct;173(4):1202-9. doi: 10.2353/ajpath.2008.080101. Epub 2008 Sep 4.
257	AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease.J Leukoc Biol. 2015 Aug;98(2):173-84. doi: 10.1189/jlb.3RU0215-074R. Epub 2015 Jun 5.
258	Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease.Am J Gastroenterol. 2019 May;114(5):777-785. doi: 10.14309/ajg.0000000000000237.
259	Platelet hyaluronidase-2 regulates the early stages of inflammatory disease in colitis.Blood. 2019 Aug 29;134(9):765-775. doi: 10.1182/blood.2018893594. Epub 2019 Jul 1.
260	Regulation of IL-22BP in psoriasis.Sci Rep. 2018 Mar 23;8(1):5085. doi: 10.1038/s41598-018-23510-3.
261	Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011 Sep 9;89(3):432-7. doi: 10.1016/j.ajhg.2011.07.022. Epub 2011 Aug 11.
262	COPs and POPs Patrol Inflammasome Activation.J Mol Biol. 2018 Jan 19;430(2):153-173. doi: 10.1016/j.jmb.2017.10.004. Epub 2017 Oct 10.
263	Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis.Hepatology. 2007 Jun;45(6):1538-46. doi: 10.1002/hep.21697.
264	Dynamic Contrast-Enhanced MR with Quantitative Perfusion Analysis of Small Bowel in Vascular Assessment between Inflammatory and Fibrotic Lesions in Crohn's Disease: A Feasibility Study.Contrast Media Mol Imaging. 2019 Feb 4;2019:1767620. doi: 10.1155/2019/1767620. eCollection 2019.
265	PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing.Nat Immunol. 2018 Sep;19(9):942-953. doi: 10.1038/s41590-018-0179-y. Epub 2018 Aug 13.
266	PSTPIP2 Inhibits the Inflammatory Response and Proliferation of Fibroblast-Like Synoviocytes in vitro.Front Pharmacol. 2018 Dec 4;9:1432. doi: 10.3389/fphar.2018.01432. eCollection 2018.
267	Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39.BMC Med Genet. 2014 Jun 27;15:73. doi: 10.1186/1471-2350-15-73.
268	KLF4 activates NFB signaling and esophageal epithelial inflammation via the Rho-related GTP-binding protein RHOF.PLoS One. 2019 Apr 18;14(4):e0215746. doi: 10.1371/journal.pone.0215746. eCollection 2019.
269	Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression.Sci Rep. 2018 Apr 3;8(1):5522. doi: 10.1038/s41598-018-23623-9.
270	Semaphorin 3F Promotes Transendothelial Migration of Leukocytes in the Inflammatory Response After Survived Cardiac Arrest.Inflammation. 2019 Aug;42(4):1252-1264. doi: 10.1007/s10753-019-00985-4.
271	Expression of hypoxia-induced semaphorin 7A correlates with the severity of inflammation and osteoclastogenesis in experimentally induced periapical lesions.Arch Oral Biol. 2017 Mar;75:114-119. doi: 10.1016/j.archoralbio.2016.10.032. Epub 2016 Oct 29.
272	Innate immune adaptor MyD88 deficiency prevents skin inflammation in SHARPIN-deficient mice.Cell Death Differ. 2019 Mar;26(4):741-750. doi: 10.1038/s41418-018-0159-7. Epub 2018 Jul 23.
273	Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness.J Neurol Sci. 2011 Aug 15;307(1-2):127-31. doi: 10.1016/j.jns.2011.04.024. Epub 2011 May 24.